SmokeFreeBrain will develop and support a collaborative health-ecosystem by bringing together the relevant key stakeholders who will testify on their changing interactions and endorse the implemented interventions to ensure maximum health benefits.
At the policy level, alliance with National healthcare policy makers will capitalize efforts and scale up interventions in a global context. The institutional stakeholders are hospitals, health service providers and national authorities who monitor existing approaches to prevention or develop treatments. The scientists’ stakeholders include the scientific community (e.g. researchers, academics) and cross-sectoral experts (e.g. researchers on environmental effects). The Pharmaceutical stakeholders group includes the commercial actors (pharmaceutical industry, insurers). The individual level includes the So-Lo-Mo community, existing smoking cessation networks, family and friends, while central to all this ecosystem is the patient/smoker himself.
SmokeFreeBrain will inform all levels of the framework by providing access to real and valuable information on the establishment of effective interventions for the prevention and treatment of lung diseases.
